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Bronchioloalveolar carcinoma (BAC) develops from terminal bron-
chiolar and acinar epithelia, growing along alveolar septa but without
evidence of vascular or pleural involvement. A final diagnosis of BAC
can only be achieved from a surgical specimen. Problematically, BAC
may exhibit multifocal involvement by means of diffuse aerogenous
metastatic spread, making this definition inapplicable for patients with
stage IIIB to IV disease from whom only small size biopsy or cytolog-
ical specimens are obtained. The recent interest and potential impor-
tance of BAC and the related peripheral adenocarcinoma (ADC), mixed
subtype, is attributable to mounting evidence that some, perhaps many,
of what are called peripheral ADCs have arisen from and often contain
BAC. BAC, in turn, appears to arise from smaller peripheral nodules,
called atypical adenomatous hyperplasia. These developments could
account for part of the increase in ADCs noted in some countries, in
particular, in East Asia. Interest also stems from the observation that
advanced ADC, often with BAC features, are responding in surprising
fashion to tyrosine kinase inhibitors. Furthermore, some of the more
rapid, dramatic, and durable responses occur when specific mutations in
the epidermal growth factor receptor are present. Clinical characteristics
often differ from other types of non-small cell lung cancers. These
include frequent female occurrence, especially in East Asians; no or less
smoking history; an often indolent course; distinctive chest computed
tomographic findings; frequent presentation as an asymptomatic, some-
times small, peripheral nodule(s)/mass; multifocal/synchronous pri-
mary tumors; and less frequently as pneumonic-type consolidation or
diffuse, inoperable lesions, the latter two often with bronchorrhea, and
with chest-only disease. Relapses also are predominantly pulmonary,
perhaps related to aerogenous spread, and responsible for mortality.
Lobectomy is the treatment of choice for cure, even with pneumonic
consolidation, but lesser procedures such as wedge resection or
segmentectomy may be considered for what might be multifocal,
synchronous primary tumors and for pulmonary relapses. Because
of frequent lung-only recurrences, lung transplantation, although per-
formed rarely, may hold promise.
(J Thorac Oncol. 2006;1: 344–359)
Information concerning bronchioloalveolar carcinoma(BAC) is coming at a rapid pace. Problematically, however,
most BAC literature published before 2000 must be inter-
preted cautiously because diagnostic criteria were revised by
the World Health Organization (WHO) and the International
Association for the Study of Lung Cancer (IASLC) in 1999
and 2004.1 By this definition, BAC is considered a subtype of
peripheral pulmonary adenocarcinoma (ADC), developing
from terminal bronchiolar and acinar epithelia and progress-
ing in a lepidic and/or aerogenous manner, but with no
stromal, vascular, or pleural invasion. A final diagnosis can
only be achieved based on a surgical specimen, excluding
many cases previously diagnosed as BAC.
Lepidic/aerogenous spread, a BAC hallmark, is ob-
served also in the putative precursor of nonmucinous BAC
(NM-BAC), atypical adenomatous hyperplasia (AAH), in
BAC with an element of presumed invasion (Noguchi type
C),2 and in ADC, mixed subtype, which often contains BAC
features (ADC-WBF). This has led to speculation that BAC is
often the precursor of ADC-WBF, the most common type of
non-small cell lung cancer (NSCLC) in many countries.3,4
Such spread is also seen in pneumonic-type adenocarcinoma
(P-ADC), which usually has some degree of BAC, and in
what have been called “diffuse” and “multifocal” BACs.
Some have suggested that BAC is increasing,5–7 al-
though in most recent studies this has not been seen.8,9
Compared with other types of NSCLC, patients in this spec-
trum often have a lesser or nonsmoking history, female
preponderance, different etiologic and racial factors, a wider
range of clinical presentations, less frequent nodal and ex-
trathoracic spread, and usually a more indolent course and
favorable prognosis. With increasing use of high resolution
spiral computed tomography (HRCT),10–13 BAC, Noguchi
type C and, less often, ADC-WBF are being found, present-
ing as nonsolid lesions, also termed ground-glass opacities
(GGOs), with smaller such lesions being AAH.14 There is
increasing information concerning molecular biology that is,
in many respects, specific to the BAC spectrum. This may
permit selection of specific therapies, such as epidermal
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growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs). These seem more effective with advanced ADC-
WBF, in nonsmokers, female patients, and East Asians com-
pared with other NSCLC.15
It is the goal of this review to discuss the literature
concerning the epidemiology, pathology, molecular biology,
clinical presentations and natural history, imaging, surgical
treatment, prognostic factors, and systemic therapy of the
BACs. We hope that this will lead to a better understanding
of this spectrum and its clinical and biological relationship to
ADC.
PATIENTS AND METHODS
We searched MEDLINE and MDConsult (Elsevier)
using the key words “bronchioloalveolar carcinoma.” Studies
in English through December of 2005 were reviewed and
cited, including a National Cancer Institute/IASLC–spon-
sored BAC meeting in November of 2004. In the main,
studies with the words bronchioloalveolar carcinoma in the
title were cited. However, there was inclusion of some studies
with significant numbers of BAC patients with presumed or
real invasion, because pure BAC, per se, is infrequent. These
included phase I and II therapeutic studies. Studies involving
BAC-like cell lines were kept to a minimum, as were ab-
stracts. Where and whenever possible, criteria used to make
the diagnosis of tumors with BAC features were noted. The
term “peripheral pulmonary adenocarcinoma” was also used.
On occasion, intrainstitutional criteria for BAC were used
and noted.
EPIDEMIOLOGY
Incidence
What has been called BAC represents 2 to 5% of all
lung carcinoma (LC),9,16–20 although some have suggested
that the incidence is increasing.5–7 Surveillance, Epidemiol-
ogy, and End Results data from 1979–1998 show a slight
increase, but remaining below 4% of all U.S. LC.8 BAC may
show some real increase in Japan, in particular, with more use
of low-dose HRCT screening, because the majority of LCs so
discovered are BAC or Noguchi type C.10–13
Age and Gender
Most epidemiologic studies report a female predomi-
nance,8,9 as do some other studies.5,18,21–24 However, a num-
ber of other studies show a male predominance.7,16,19,20,25–34
In one, female patients may be younger.34 Factors such as
race and ethnicity might explain these differences.
Smoking
Smoking is a risk factor, with most studies reporting 44
to 85% having a history.7,9,16,17,20–23,25–28,31,33–37 However, in
several series, the proportion of nonsmokers is higher36 and
smoking intensity is lower18,25,26,36 compared with other
NSCLC. In one P-ADC study, almost all female patients were
nonsmokers (17 of 18 [95%]).28 Finally, NM-BAC is asso-
ciated with smoking,7 whereas those with mucinous BAC
(M-BAC) tend to be nonsmokers.27
Underlying Pulmonary Disorders
Prior tuberculosis may be a risk factor for NM-
BAC.7,28,33 Twenty-five percent of connective tissue disease–
associated LCs are BAC, most having progressive systemic
sclerosis with related pulmonary fibrosis.38 However, the
prevailing concept is that, with no underlying pulmonary
disorder, scars are secondary to the cancer.39,40
Congenital pulmonary airway malformation, type I,
may be a precursor lesion of M-BAC because it can appear in
areas of congenital pulmonary airway malformation. This
type of BAC presents at a mean age of 26 years. Recurrences
and mortality following resection are unusual.41
Infectious Cause
Jaagsiekte, or ovine pulmonary adenocarcinoma, simi-
lar to P-ADC except for having a greater papillary compo-
nent, occurs in sheep and is caused by the respiratory beta-
retrovirus, Jaagsiekte sheep retrovirus (JSRV). Excessive
production of surfactant proteins by alveolar tumor cells
results in bronchorrhea. There is sheep-to-sheep spread and
progressive disease progression, but sheep-to-human trans-
mission has not been reported. JSRV envelope protein func-
tions as an oncoprotein, activating proliferative and survival
pathways.42 Neither JSRV DNA nor RNA has been found in
human BAC.43
Thus, there are efforts to determine whether an infec-
tious agent, such as human papillomavirus,44,45 is responsible
for the increase in BAC-type tumors seen, in particular, in
nonsmoking female patients, especially those from East Asia,
because the relationship of smoking to BAC is less than with
other types of LC.
PATHOLOGY
BAC
The current (2004) WHO1 classification defines BAC
as “an adenocarcinoma with a pure bronchioloalveolar
growth pattern and no evidence of stromal, vascular, or
pleural invasion.” The characteristic bronchioloalveolar
growth (Figure 1A) involves not only spread of cells along
alveolar septae, a pattern referred to as “lepidic,” but also
implantation of cells at sites noncontiguous with the primary
tumor, a pattern referred to as “aerogenous spreading.” If
small, these lesions may not be visible by conventional
imaging methods, a potential source of understaging.
By contrast, invasive tumors elicit a vigorous fibrous
response, recognized by the presence of loose, proliferative
fibrosis. Fibrosis must be distinguished from alveolar col-
lapse, consisting of hypocellular elastic nodules without ev-
idence of active fibrosis. This distinction is important be-
cause, at least in the Japanese experience, fibroblastic foci
larger than 2.0 mm reduce 5-year survival from 100% to
75%.2
Most cases reported to be BAC before the 1999 clas-
sification probably demonstrated some evidence or degree of
invasion and should have been considered to be ADC-
WBF.1,46 Furthermore, most tumors reported to be BAC by
the increasingly used fine needle aspiration biopsy or trans-
bronchial biopsy28,47 were probably ADC-WBF because suf-
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ficient tumor was not provided to definitively exclude inva-
sion.48,49 This can be a significant problem because up to 80%
of ADCs arising in peripheral airways are currently “adeno-
carcinoma with mixed subtypes” and usually contain some
BAC.
The cell type may be NM-BAC (most often), M-BAC,
or a mixture of the two (unusual). NM-BAC has cells with
features of Clara cells or of type II pneumocytes. Clara-like
tumor cells (Figure 1B) are columnar and eosinophilic, with
apical cytoplasmic extensions (“snout”) projecting above ep-
ithelium. Type II pneumocyte-like tumors (Figure 1C) con-
tain cells that are cuboidal or low columnar and may have
foamy or vacuolated cytoplasm. Nuclei are located centrally,
are usually of low grade, and have infrequent mitoses.
Whether a tumor is composed of Clara cells or type II
pneumocytes does not seem to be clinically significant.1 Cells
of M-BAC (Figure 1D) are evenly distributed along alveoli in
single layers. Their nuclei are also low grade and may be
compressed by large cytoplasmic vacuoles, making nuclei
difficult to visualize. Surrounding alveoli often contain mu-
cous pools.
Atypical Adenomatous Hyperplasia and the
Origin of Some BAC
AAH was incidentally discovered in lungs resected for
invasive ADC and proposed as a possible precursor of pe-
ripheral ADC,3,4 a hypothesis not yet confirmed. Lesions are
usually 5 mm or smaller50 and found in lungs removed for
LC1 but are also found in elderly patients without LC.51 The
epithelium is abnormal by morphometric analysis and flow
cytometry.4,52–55
AAH frequency is difficult to determine because of its
small size, presentation as an incidental finding, and inacces-
sibility in peripheral lung. This limits detection, resulting in
lack of longitudinal studies with which to determine its
significance. In lungs resected for LC, its incidence is 5 to
20%.4 The gender correlation of AAH and ADC is un-
clear.56–58 AAH is usually associated with ADC4,56–58 and
with prior malignancies in general.56 Its incidence is 2 to 4%
in general autopsies59,60 but up to 35% in resected ADC
specimens.1 AAH, along with NM-BAC, is a relatively fre-
quent finding at the periphery of ADC.18,30,50
AAH, like BAC and ADC, often demonstrates K-ras
mutations,61 loss of heterozygosity (LOH) at sites of putative
tumor suppressor genes (TSG) at specific chromosomal
sites,62–65 and chromosomal imbalance by comparative
genomic hybridization.4 The higher frequency of AAH asso-
ciated with ADC and BAC66 suggests that AAH is a precur-
sor of some BAC and ADC, a hypothesis supported by the
similarity in molecular profiles between AAH and BAC,
especially high-grade AAH.4,67,68 It should be noted that
AAH is a putative precursor only of NM-BAC.69–71
MOLECULAR BIOLOGY
The molecular bases underlying lepidic growth and
aerogenous progression of BAC-type tumors are unclear.
Most reports before the 1999 WHO/IASLC classification46
concerned BAC-containing tumors or ADC with lepidic/
aerogenous growth, whereas more recent articles focus spe-
cifically on pure BAC, Noguchi type C (mainly Japanese
literature), or ADC-WBF.
Insensitivity to Antigrowth Signals, Cell Cycle
Progression, and Evading Apoptosis
p53 is mutated less frequently (25%)72 in resected
BAC-containing tumors than in other LC.73 Its overexpres-
FIGURE 1. Pathology slides of
BAC cells. (A) BAC, low power; (B)
Clara-like tumor cells; (C) Type II
pneumocyte-like tumor cells; (D)
mucinous BAC tumor cells.
D. H. Garfield et al. Journal of Thoracic Oncology • Volume 1, Number 4, May 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer346
sion parallels the increase in invasion from AAH to BAC to
ADC-WBF.74–78 p53 abnormalities seem more associated
with NM-BAC.44,72,76,78 Loss of TSG function during devel-
opment may be from chromosomal LOH. LOH on 17p, the
p53 locus, and other loci also increase with degree of inva-
sion. Tumor cells in peripheral areas exhibit less allelic losses
than in central fibrotic areas, where invasion is presumed to
already have occurred.79
Aberrant methylation/silencing of CpG islands of the
promoter region of TSG, p16, are associated with progression
of BAC to ADC-WBF. Both events lead to diminished p16
expression. This may occur early and is associated with
smoking,80 although loss of expression is infrequent in
AAH.81
Cyclin D1 overexpression is greatest in AAH but de-
creases with progression to BAC to invasion, suggesting its
importance as an early event but not a necessity for tumor
development and maintenance.81 Proliferation-related pro-
teins, eukaryocytic initiation factors 4E and 2,82,83 and
neutral large amino acid transporter type 184 also increase
with degree of invasion.
Recent data suggest that AAH and BAC are character-
ized by resistance to physiologic apoptosis and replicative
senescence. Expression of survivin,85 telomeric repeat bind-
ing factor1,86 and the two subunits of telomerase, human
telomerase RNA component and human telomerase reverse
transcriptase,87 all increase with invasion.
Self-Sufficiency in Growth Signals for
Receptors
Activating EGFR somatic point mutations or deletions/
insertions account for many TKI responses. Most NSCLC
patients, the majority with BAC features, all NM, with major
responses to TKIs compiled from recent studies, have these
genetic alterations. Two patients with advanced ADC-WBF
having EGFR mutations conferring TKI sensitivity subse-
quently developed an EGFR kinase domain mutation,
T790M, in exon 20, which conferred drug resistance. One
had initially responded to erlotinib.88 In resected specimens,
EGFR genetic alteration rates vary greatly. They seem less
frequent in BAC than with invasion (0% versus 27%),89 (13%
versus 28%),90 (53% versus 87%),91 but are decreased in
ADC.91,92 However, in Japanese patients, EGFR mutations
are more frequent in Noguchi types A and B for reasons that
are unknown.93 Mutations are also seen in normal-appearing
epithelium in ADC-WBF.94 High polysomy and gene ampli-
fication (fluorescence in-situ hybridization [FISH]) of EGFR
are seen in 33 to 44% of stage IIIB to IV NM-BAC but in
only 4% of M-BAC, and are associated with increased sen-
sitivity to gefitinib.95–97
Another tyrosine kinase receptor, c-met, and its ligand,
hepatocyte growth factor (HGF), are overexpressed in BAC-
containing tumors.98–101 Activation of the HGF/c-met path-
way leads to invasive growth. Diffuse BAC-containing tu-
mors contain more HGF as compared with solitary BAC.98
High HGF is also found in bronchoalveolar lavage fluid in
P-ADC.28
Activating K-ras mutations do not increase from AAH to
invasion, suggesting that this is an initiating event.3,61,102,103
They are seen to a similar degree (27%) in resected ADC-
WBF92 as in those with advanced disease (30%).104 Mutations
are more frequent in M-BAC (76%) than in NM-BAC (14–
17%).92,105 However, mutation types and rates vary from M-
BAC to NM-BAC, from country to country, within countries,
and independent of but usually related to tobacco exposure.
Finally, few patients (0–6%) have tumors harboring mutations
of both K-ras and EGFR.104–106
Aerogenous Spread versus Tissue Invasion
Tumor cell-matrix interaction might be important in
transition of BAC to invasion. There is basement membrane
(BM) type IV collagen damage even in Noguchi type A,
which progresses through type B to C. Loss of type IV
collagen is caused by tumor-derived matrix metalloproteinase
(MMP)-22,107–110 and MMP-9. Their source may be stromal
cells, suggesting stromal involvement as an early event in
invasion.111 In progression of AAH to BAC, loss of beta-
catenin expression, followed by E-cadherin, are early events,
seen even before evidence of alveolar destruction. E-cadherin
loss, then, seems important for tumor progression.112
In M-BAC, there are high levels of type IV collagenase
and low 2 integrin, perhaps explaining the ability of M-
BAC cells to detach from BMs and spread aerogenously
rather than by invasion.19,113 Dysregulation of mucin expres-
sion also seems important in aerogenous spread of M-BAC.
The transmembrane mucin, MUC1, modulating cell-cell and
cell-matrix adhesion, is down-regulated and depolarized in
progression from AAH to BAC to invasion. This blocks
cell-cell and cell-matrix adhesion, leading to tumor cell
motility and invasion.
Inflammatory Host Reaction
Lepidic growth and aerogenous progression are associ-
ated with specific host reactions. Tumor-infiltrating macro-
phages increase from AAH to BAC to invasion, suggesting
their role in tumor development.103 Neutrophil recruitment is
seen in alveolar spaces of P-ADC. Their maintenance may be
from tumor cell secretion of chemotactic factors C-X-C
chemokines, interleukin-8, and epithelial cell-derived neutro-
phil-activating protein-78, and the anti-apoptotic factors
granulocyte-macrophage (GM) colony-stimulating factor
(CSF) and G-CSF. Alveolar macrophages, perhaps stimulated
by adjacent tumor cells, also produce interleukin-8, epithelial
cell-derived neutrophil-activating protein-78, GM-CSF, and
G-CSF. Alveolar macrophages, endothelial cells, and fibro-
blasts express high levels of tumor necrosis factor , which
can induce or amplify chemotactic and anti-apoptotic factor
expression by BAC cells.28,99 Among locally produced cyto-
kines, GM-CSF degranulates neutrophils, resulting in release
and accumulation of HGF, neutrophil elastase, and reactive
oxygen and nitrogen species. The latter two can damage
DNA, activate oncogenes, and promote tumor progression.
Tumor-infiltrating mast cells are associated with BAC pro-
gression and invasion. These secrete angiogenic factors
tryptase and chymase. The latter, especially, can activate
MMPs for matrix remodeling.114
Although based on broad BAC definitions, recent stud-
ies demonstrate more specific molecular abnormalities with
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therapeutic implications. EGFR and downstream pathways,
such as K-ras, seem most involved, making them therapeutic
targets. Tumor-infiltrating inflammatory cells, including al-
veolar and tumor-infiltrating macrophages, neutrophils, and
mast cells are involved in aerogenous and invasive progres-
sion. These also could be targets for future therapeutic strat-
egies.
CLINICAL FINDINGS
Presentation and Natural History
Up to 71% present without symptoms7,16,17,21,24,27,31
and 39 to 73% have stage I disease,7–9,16–19,21,24,27,34,115,116 the
tumor having been found either by chest radiographs being
taken for other reasons or by screening computed tomo-
graphic (CT) scanning.10–13
Symptoms make stage III/IV34 more likely and are
usually present with P-ADC28 and the diffuse forms. Of
patients with symptoms, approximately 25 to 70% present
with cough.16,17,24,27,29,34 Other presenting symptoms are less
frequent, occurring late. These include hemoptysis (23%, but
minimal), weight loss (25%), weakness (20%), and anorexia
(8%).117 Dyspnea with severe hypoxia may not represent
extensive, terminal, end-stage disease because it may result
from a right-to-left shunt, with disease localized to one lobe
or one lung. Fever is present in approximately 9%, usually
from secondary pneumonia.117 Two-thirds of patients with
unresectable disease produce sputum.25 Bronchorrhea (100
cc/day) is typical but infrequent (5%),19,26,27 except in P-ADC
(31%).28 It has been seen with both M-BAC39 and NM-
BAC.118,119 Duration of symptoms can be quite long, from at
least 1 year in approximately 40% of cases, to more than 2
years in 23%, to as long as 4 years in approximately 10%, in
keeping with the notion of BAC being slowly progressive.117
Many have a good performance status until late.26,32,117
Even with advanced disease at presentation, nonpulmo-
nary metastases are uncommon, although the range is wide
(6–32%).9,23,25,26 Metastatic sites at presentation include bone
(4–28%), adrenal (16%) and, less frequently, brain (0–8%)
or liver (0–4%).9,23,25,26 Stage I patients are almost fourfold
less likely to develop extrathoracic recurrences than other
types of NSCLC,36 while extrathoracic recurrences are more
likely with stage III/IV disease.7 Recurrences develop after a
mean of 14 to 30 months,17,24,25,28 usually within 3 years,33
but can occur late, more than 2 years after resection17,24,28 in
good-risk patients with no/less smoking history and/or after
limited resection. Recurrences are mainly lung, either ipsilat-
eral or contralateral,17,20,22,24,36 but intrathoracic node recur-
rences are infrequent.7,17,24,36 Of those with local recurrences,
65% were found more than 3 years after surgery,33 whereas
disease in patients with P-ADC recurs the most rapidly
(median, 18.7 months) and usually in the lungs.22 Extratho-
racic metastatic sites are relatively infrequent, being most
often in bone (up to 28%)7,23,25,26,28,29,36 and brain
(8–15%).23,25,26 Other metastatic sites are rare.23,25,26
As regards the natural course of BAC-type tumors,
sometimes a nodule/mass has been present for up to 12 years
before diagnosis16,31 and, even in some types of advanced
disease, median survival (MS) approaches 1 year or
more.9,26,23,120 Death often occurs from devolution from one
type (nodule/mass, P-ADC) into the diffuse type, sometimes
rapidly, more often with the mucinous type.121,122 There is a
25% risk of second primary LC, usually after stage I, and
often late (8–12 years).22,31,123
Thus, BAC-type tumors appear in two distinct forms.
Some are asymptomatic, the disease being found by chest
radiography or CT screening, usually as a nodule/mass. Some
others have dyspnea and bronchorrhea, manifesting radiolog-
ically as P-ADC, either unifocal or multifocal, as diffuse
pulmonary disease, or with distant metastases.9 Whichever
the presentation, extrathoracic metastases at diagnosis or
relapse are infrequent. However, lung metastases are com-
mon and usually responsible for death.
IMAGING
BAC-containing tumors present in three forms: nodule/
mass (43%) (Figures 2A and 3A, B, and D), regional pneu-
monic/consolidation (30%) (Figures 2B and 4B and C), and
diffuse dissemination throughout the lungs (27%) (Figure
4D).124 All three may be bilateral and have combinations of
the three (Figure 4A–D).125–128
CT Scanning
CT scanning, although 90% specific for a BAC diag-
nosis, is not sensitive in detecting all disease.129 Using con-
ventional CT scanning, unsuspected tumors and premalignant
lesions have been found in lobectomy specimens. In speci-
mens removed for BAC-type tumors, one-third found patho-
logically were not detected by CT scanning and, in 43%,
additional neoplasms were found, mainly AAH and BAC,
often away from the CT scan detected tumors, mainly NM-
BAC, and 1 to 2 mm.130 By contrast, some clinical stage I
patients were often upstaged pathologically (56%), demon-
strating the lack of CT scan accuracy18 and, in another study,
12 of 55 cases were felt to have multiple lesions by CT
scanning, but this was so pathologically in only six.7
Mass/Nodule
Presentation is usually as an upper lobe nodule/mass,
but the range is wide (11–85%), higher in surgical and lower
in medical series (Figures 2B and 3A, B, and D). A mass may
be more frequent than a nodule.19,24 Part of the lesion may not
completely obscure the lung parenchyma within it, that por-
tion being called “ground-glass opacity” (GGO), or nonsolid
(Figure 3A, B, and C)131 or “ground-glass attenuation”
FIGURE 2. Radiographic evidence of (A) mass and (B)
pneumonic/consolidation.
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(GGA).132 Histopathologic correlation of GGO with BAC is
unclear.
Solitary BACs appear to evolve from being small, with
up to 100% GGO (highest predictive value), to being larger
and semisolid, with GGO forming a “halo” around the solid
portion (most frequent presentation) (Figures 3D and 4A),
and finally to a greater degree of solid component as in
ADC-WBF.131 If pure BAC, the solid component may be
from collapse or severe narrowing of alveolar spaces. With
progression, surrounding focal areas of lymphangitic spread
are seen, as are spiculations (highest predictive value for
invasion).133 Pure GGO lesions cannot be determined to be
AAH, BAC (Noguchi types A and B), ADC-WBF, or even
ADC by routine CT scanning or even HRCT.134 However,
FIGURE 3. Imaging results for
BAC-containing tumors. See text
for full descriptions of (A), (B), (C),
and (D).
FIGURE 4. Imaging results for
BAC-containing tumors. See text
for full descriptions of (A), (B), (C),
and (D).
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GGO smaller than 8 mm is probably AAH or Noguchi type
A.135,136 Most AAH and Noguchi type A less than or equal to
1.0 cm are GGO,137 but 7% of such lesions will be adeno-
carcinoma. GGO of 1.1 to 1.5 cm can be BAC or ADC but
not AAH, whereas GGO larger than 1.5 cm is probably
adenocarcinoma.135 GGO is best seen by CT.
Although pulmonary nodules are generally considered
benign if they remain the same size or decrease over 2
years,138 solitary masses have been present and often stable in
size and appearance for years, only to be discovered to be
BAC types.16,31 Some may even decrease in size but develop
a solid component.139
Spiculations surrounding a solitary lesion suggest inva-
sion and correlate with fibrosis140 (Figure 3D). Lobulation
and convergence of vessels suggest Noguchi types B and
C.137 Indistinct margins, air-bronchogram, pleural tags, ser-
pentine and bubble-like lucencies, “halo” sign, “crazy pav-
ing,”141 and pseudocavitation are also seen125 but are usually
associated with ADC-WBF rather than pure BAC.
Pneumonic BAC
Less frequently, presentation is a pneumonia-like con-
solidation (Figures 2B and 4B and C) and segmental, in-
volves an entire lobe (lobar-BAC)142 or is bilateral (58%),
and has multiple consolidations.27,28,124,142–145 An air-bron-
chogram (Figure 4C) is usually present,125,126,144 pleural ef-
fusion uncommon,126 and the primary tumor difficult to
demonstrate.27,28 The CT angiogram sign (Figure 4B) is often
seen, perhaps from an intact vascular system surrounded by
low-attenuating consolidation125 composed of mucin or other
fluid.142
Pathologically, the pneumonic component may be at-
tributable to lepidic growth, with partial filling of alveolar air
spaces by mucin or tumor cells, as in pure BAC,125,143 and an
aerogenous growth with a mixture of papillary, acinar,
and solid components associated with inflammatory cells and
fibrotic stromal reaction.28
Because of radiographic similarity to pneumonia,143–145
P-ADC may take 3 to 5.5 months to diagnose.27,28,144 Patterns
seen in P-ADC include coexisting satellite (micro)nod-
ules143,144 (Figure 3C), peripheral consolidation,126,144,146 the
CT angiogram sign125,142 (Figure 4B), and cystic air spac-
es127,141 (Figure 4C). Alteration of the bronchus within the
consolidation and bulging fissure124–126,143,144 may be more
suggestive of BAC rather than pneumonia.143
Diffuse BAC
This pattern147 is the least frequent presentation but has
a wide range of occurrence, from 7 to 36%.124–128 It is usually
M-BAC, with 1- to 3-mm nodules (Figure 4D). They can be
associated with GGO or consolidation, from which they may
have evolved.5,122,147 In approximately one-half there is a
peripheral distribution, attributed to aerogenous spread. Lym-
phangitic-like spread at this stage is common.146
Mucinous/Nonmucinous
CT scanning may help determine cell type, although
one report found no correlation between radiographic appear-
ance and cell type.116 Diffuse disease, air-space consolida-
tion, bulging fissure, open bronchus sign, air-bronchogram,
cystic air spaces, and the CT angiogram sign124–128,142,143
seem more frequent in M-BAC, whereas a nodule correlates
more with the NM-BAC.30,128
Positron Emission Tomographic Scanning
Although fluorine-18 fluorodeoxyglucose positron
emission tomographic (PET) scanning is not as useful as with
other types of NSCLC, it is positive in approximately one-
third of patients with pure BAC. Percentage positivity and
standardized uptake value increase with amount of invasion,
in multifocal tumors, mass/nodule as compared with P-ADC,
and the diffuse form. Scanning later than standard after
injection also can increase positivity.148 PET can miss pure
BAC or tumors containing a good deal of mucin and can also
miss small, diffuse lesions.149,150
SURGICAL MANAGEMENT
As with NSCLC in general, lobectomy remains the
standard of care with resectable disease except under special
circumstances (see below). All patients with incomplete re-
sections died within 5 years,17 with MS being 1.7 years.24
None undergoing open lung biopsy-only survived more than
2.5 years.21
Mediastinal Node Examination
In surgical series, N2 involvement varies greatly, from
less than 2% to 25%.7,16,17,21,32 Reasons for such wide ranges
are unclear, although most used pre-1999 criteria. With tumor
size 2.0 cm or smaller and Noguchi types A or B, nodal
involvement is rare, although N2 disease has been reported
even with T1 lesions.17,21 Therefore, although nodal disease
is less common in the BAC spectrum, mediastinal examina-
tion should be mandatory because nodal status cannot be
adequately ascertained by CT scanning or PET.
Surgery Other Than Lobectomy
Pneumonectomy
Patients undergoing pneumonectomy do poor-
ly,17,30,34,151 especially those with P-ADC,28 with very few
5-year survivors. Thus, pneumonectomy should not be con-
sidered for cure.
Lesser Surgery (Wedge Resection, Segmentectomy)
A conundrum is the extent of resection, given the often
indolent course of BAC types, and possible later pulmonary-
only recurrences and synchronous/metachronous other pri-
mary tumors. However, there is an increased risk of local
recurrences with lesser surgery.
There are six studies which deal with attempted limited
resection, all from Japan.152–157 These were performed if,
intraoperatively, there was no node involvement (usually two
to three nodes), fibroblastic proliferation (Noguchi type C),
pleural/stromal invasion, or tumor other than BAC. Other-
wise, surgery was converted to lobectomy with complete
node dissection. However, lesser procedures had to be
changed to thoracotomy in 9 to 37.5%, mainly because of
Noguchi type C being found.153,154 Eighteen percent had a
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segmentectomy by thoracotomy because of tumor location
and 2% had another surgical procedure because BAC was not
initially diagnosed as malignant on frozen section.158 In these
six studies, with a median follow-up of 29–50 months, all
patients were alive and without recurrence (Table 1).
However, even if lesser surgery is possible, there are
problems with drawing conclusions from these studies be-
cause, in most, follow-up is short in a clinical situation where
patients are at risk for recurrence for up to 10 years.154 Also,
patient numbers are small, patients are not randomized, and
tumor invasion cannot always be determined until permanent
sections are viewed.
At this time, curative treatment for early-stage BAC-
containing tumors should follow standard principals. Lesser
procedures for TI lesions are best performed only under
special circumstances such as a clinical trial, limitation of
pulmonary function, or need for surgery for multiple primary
tumors/recurrent disease (see below) or, perhaps, for nonsolid
nodules 2.0 cm or smaller, preferably 1.0 cm or smaller.154
Surgery for Special Circumstances
Surgery for Multifocal BAC
The incidence of multifocal disease in surgical series is
as high as 22 to 29%,22,159 but the disease is often unilater-
al.7,24 Recent studies have found no survival difference be-
tween resected solitary and multifocal disease, perhaps be-
cause of some multifocal tumors being managed as separate,
synchronous primary tumors. Such patients had a MS of 75
months24 and a 64 to 82% 5-year survival. Surprisingly,
mediastinal nodes were not often involved.22,24,159
Current staging for multiple BAC lesions is often in-
adequate so that, despite stage IIIB to IV disease, curative
surgery for pulmonary parenchyma-only patients should be
considered.7,22,27,159 For instance, multiple lesions in one lobe
(T4; therefore, IIIB) or involvement of multiple lobes (M1)
should be so considered and managed by bilateral lobectomy
and/or wedge resection because they may represent separate
primary tumors, not metastases. However, these should be
distinguished from diffuse disease with numerous 1- to 3-mm
micronodules, where surgery should not be considered.
Surgery for Pneumonic-Type ADC
Patients with P-ADC should be considered for surgery
even though their prognosis is generally poor.17,22,28 Recur-
rences are usually intrathoracic and more frequent than in
nodule/mass.28 In one study, 5-year survival was 27%.17 In
two others, MS was 4922 and 16 months.28
Surgery for Recurrent Disease/New Primary
Tumor
Although many pulmonary relapses present as diffuse
disease, the question of surgery for “recurrence” deserves to
be addressed because this may represent a new primary
tumor. Such recurrences often occur only in ipsilateral pul-
monary parenchyma,17,20,22,36 especially if originally a stage I
mass/nodule and more than 2 years had elapsed.27 The prob-
ability of recurrence is highest in the first 2 years, being 29%
for stage I and 67% for stage III/IV.123
Patients have been reported living with or without
recurrences for years after curative/salvage resections.21,24,34
TABLE 1. Survival Results for Lesser Surgery, Stage IA
References CT Finding Size(mm)
Operation
(No. of
Patients)
Pathologic
Findings Recurrences/Survival
Surgical Conversion
(%)
Yamato et al.,
2001152
BAC
suspected
20 Thoracotomy,
only (42)‡
Types A, B, 36;
invasion, 4
No recurrences;
median follow-up,
30 mo
6/42 (14) to lobectomy
Watanabe et al.,
2002153
Pure GGO 5–12 VATS wedge
(14)/
segmentectomy-
thoracotomy
(3)*§
BAC No recurrences;
median follow-up,
32 mo
3/17 (18) to thorocotomy
Yamada and
Kohno, 2004157
Pure GGO 20 VATS wedge
(22)
Types A, B, 20;
type C, 2
No recurrences;
median follow-up,
29 mo
1/22 (4.5) to lobectomy
Nakamura et al.,
2004156
Pure GGO 6–12 VATS wedge/
thoracotomy
(27)§
Type A, 18; type
B, 6; type C, 3
No recurrences; mean
follow-up, 32 mo
0/27 (0)
Yoshida et al.,
2005154
GGO 6–21 VATS wedge/
segmentectomy/
/thoracotomy
(40)§
Type A, 2; type
B, 23; type C,
15†
No recurrences;
median follow-up,
50 mo
11/30 (37) to
thorocotomy, 14/40
(35) for type C
Nakata et al.,
2005155
GGO90–100% 5.6–18.4 Wedge, 15;
segmentectomy,
1;lobectomy, 7
All noninvasive All alive; no
recurrences;
median follow-up,
24.5 mo
0/23
*Three of 17 converted to segmentectomy by thoracotomy. †Fourteen of 15 converted to formal lobectomy with node dissection. None had positive nodes. ‡Node sampling
routinely performed. §No routine node sampling. Node sampling in some cases. VATS, video-assisted thoracic surgery.
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Those undergoing multiple operations for recurrences sur-
vived more than 50 months after the first operation,21 and
those having second resections for a nodule/mass had a
postoperative MS of 105 weeks. However, patients having
salvage operations for multiple nodules, P-ADC, diffuse
disease, or lymphangitic spread had short survivals.34
Palliative Surgery
This has been performed, usually in M-BAC, because
of hypoxia caused by a right-to-left shunt. With disease in
one lobe, one lung, or diffusely in both lungs (one side being
more involved), patients have had relief of symptoms for up
to 10 months, with survival of up to 18 months160 after
lobectomy161 or even pneumonectomy.160
Lung Transplantation
This is appealing because of frequent pulmonary-only
spread and the relatively low incidence of nodal and distant
metastases. A review of 26 cases, all with diffuse disease and
impending respiratory failure, reported 39% 5-year and 31%
10-year survivals. The median age was 44 years. Most did not
smoke and were female. Of 22 surviving surgery, disease
recurred in 13 at a median of 12 months, and these patients
died at a median of 22 months after transplantation, usually as
a result of respiratory failure from lung-only disease. In spite
of immunosuppression, a late and slow progression of recur-
rences was noted. Transplantation is an option for selected
patients, especially young, nonsmoking females with impend-
ing respiratory failure caused by advanced, multifocal/diffuse
BAC.162
Thus, surgery for BAC-spectrum tumors should be
restricted to (bi-) lobectomy, with special circumstances be-
ing considered on a case-by-case basis in a multidisciplinary
setting. Limited surgery and pneumonectomy have greater
risks of ipsilateral and contralateral relapse, respectively.
Multifocal disease must be distinguished from diffuse BAC,
as it has a better prognosis and might represent multiple,
synchronous primary tumors requiring multiple, simulta-
neous resections. In diffuse disease, only surgery for pallia-
tion should be considered. With recurrence, surgery, includ-
ing transplantation, should be considered but usually when
late, it is a nodule/mass, or possible new primary tumor.
PROGNOSTIC FACTORS
BAC-containing tumors seem to have a better prognosis
compared with other NSCLC, even when adjusted for stage,
although overall 5-year survival in recent resected-disease series
ranges from 34 to 74%, probably because BAC criteria vary,
many using pre-1999 criteria7,16,17,21,22,28,29,34,159,163,164 (Table 2).
Using mainly 1999 criteria, overall survival (OS) is greater than
53 months, being 72.5% at 1 year, 63% at 2 years, and 41% at
5 years, although 80% die as a result of their disease.9 Prognostic
factors should be considered to determine follow-up and subse-
quent therapy. These have assumed greater importance because
of recent positive adjuvant cytotoxic NSCLC studies suggesting
improved survival165 and because of some survival results with
TKIs in advanced disease, including Noguchi type C and ADC-
WBF.
TNM Staging
Using mainly 1999 criteria, recent 5-year prognosis for
stage I is 70 to 100%, with MS not yet reached.9 Some studies
have suggested that prognosis for stage IA versus stage IB
disease does not seem significantly different, either for
5-7,16,17,21,27,34 or for 10-year survival.27 However, one did
find a difference24 and another found a trend.19 Most used
pre-1999 criteria. As expected, 5-year survival for stage I
nodule/mass was higher versus stage II/III,116 stage I/II ver-
sus stage III/IV,22 stage I versus stage III,16,17,19,29 and stage
III/IV versus stage X (size of primary indeterminate, usually
P-ADC).22 In these studies, also, invasion was either included
or permitted.
However, current TNM staging seems inadequate for
stage IIIB/IV. In a recent study mainly using the 1999 WHO
TABLE 2. Survival in Recent Surgical Series for Resected BAC-Containing Tumors, All Stages
References
No. of
Patients
5-Year
Survival (%) Special Circumstances/Survival/Comments BAC Criteria
Regnard et al., 199817 61 34* Stage I, 56%; stage IIIA, 8%, P-ADC, 27% Pre-1999
Dumont et al., 199816 97 48 Stage I, 65%, stage II–IIIA, 20% Pre-1999
Okubo et al., 199921 119 69 56.5% 10-yr Pre-1999
Liu et al., 200034 93 55 Stage I, 68% 5-yr; stage II–IV, 30% 4-yr Pre-1999
Carretta et al., 200129 42 54 Stage I, 80% 5-yr 1999
Breathnach et al., 200136 33 83 Stage I, only 1999
Castro et al., 2001164 94 62 Stage I and II, only Institutional
(50% BAC)
Ebright et a., 200222 100 74 P-ADC, 49 mo MS; multifocal, 70%; stage I, 84%,
I–II  III–IV 5-yr
1999
Furak et al., 20037 67 62 Stage I, 75%; multifocal, 82% Pre-1999
Roberts et al., 2003159 14 64 All multifocal disease Pre-1999
Wislez et al., 200328† 19 65* All P-ADC 1999
Rena et al., 200320 28 81 Stage I, only; stage IA, 92%; stage IB, 75%§ 1999
Sakurai et al., 2004163 25 100 Stage IA, only 1999
*Less than 10% for patients having pneumonectomy. †All P-ADC. §Difference not significant.
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classification, the type of stage IIIB/IV disease was prognos-
tically important. Those with stage IIIB (same lobe) had an
82% survival at both 1 and 2 years, with OS not yet reached.
Stage IV patients (intrapulmonary) had an OS of 13 months,
a 1-year survival of 51%, and a 2-year survival of 36 percent.
However, those with distant disease had an OS of 5 months,
with 1-year survival of 27% and 2-year survival of 8 percent.
These differences were all significant.9
Prognostic Factors for Resected Disease
Clinical and Radiologic Factors
Age younger than 60 years,27 gender (both male36 and
female7,27,34), and smoking34,36 have a marginal negative
effect on survival in resected patients, although recently
female patients and never-smokers had better survivals.9
Symptoms marginally affect prognosis in some stud-
ies17,21,24,115 but not others.7,27,34 Of symptoms, short-term
weight loss and copious sputum are negative predictors for
survival,114 as are bronchorrhea and rales in P-ADC.28
For stage I, HRCT gives prognostic information that
correlates with histologic characteristics. Lesions that are 1.0
cm or smaller152,166 and with pure GGO have 100% disease-
free survival.140,167 In lesions 2.0 cm or smaller, the degree of
GGO correlates with survival.168 In lesions 3.0 cm or smaller,
the degree of GGO (50%) and the presence of lobulation on
air-bronchogram, correlating with a more pure BAC component,
also have an improved survival.169,170 However, coarse spicula-
tion and thickening of bronchovascular bundles around tumors
are associated with worse survival. Finally, solitary nodules
carry better prognoses than infiltrates16,17,19,21,22,116 or lym-
phangitic spread.34
Pathologic Factors
BAC Component
The relationship of percentage BAC to prognosis is
controversial.21,29,171 In a T1 lesion, if BAC constitutes more
than 50%, 5-year survival is 95 to 100%.2,75,172–174 Although
another study of all stages was not able to demonstrate a
survival difference according to degree of BAC,22 another
showed that survival was improved if there was at least 50%
BAC in stage I/II.164 A papillary pattern greater than 25%172
and a micropapillary pattern worsen prognoses in Noguchi
type C and ADC-WBF lesions 2.0 cm or smaller.175
Cell Type
Whether mucinous (or mixed, with both cell types)
tumors have a worse prognosis is debatable, with some
showing mucinous to be worse,22,24,29,176,177 others showing
no difference,16,17,21,27,30,116 and one finding mixed tumors to
have the worst prognosis.7 M-BAC may have a worse prog-
nosis because it is felt to present with more advanced stage,
mainly related to aerogenous spread.5,122,177 Furthermore,
NM-BAC tends to have a more favorable outcome when
thyroid transcription factor 1 is strongly expressed as com-
pared with less or no expression, whereas M-BAC does not
express thyroid transcription factor 1.178
Fibrosis
The consensus is that the presence and extent of fibrosis
in T1 tumors correlates with worse prognosis. Five-year
survival with fibroblastic scar smaller than 5 mm is 100%.
However, 5-year survival is 72% when the scar is 5 to 15 mm
and 57% when it is larger than 15mm.179
Other Pathologic and Biologic Factors
A number of other factors have been evaluated for
prognosis, including pathologic factors (tumor cell shedding,
tumor-infiltrating neutrophils, mast cells),24,28,99,114,176 ge-
netic alteration factors (overexpressed/mutated p53 and
EGFR, overexpressed HER2 and squamous cell carcinoma-
related oncogene),44,72–74,78,180 biologic factors (E-cadherin
and beta-catenin expression, depolarized MUC1, ratio of
p16/cdk4), and extracellular matrix alteration factors (colla-
gen IV, tumor MMP-2).107,112,181,182 However, these must be
reevaluated in large prospective studies including all prog-
nostic factors and multivariate analyses.
Prognostic Factors for Recurrent, Unresectable,
or Advanced Disease
In advanced disease, negative factors include male
gender and the presence of symptoms. Pretreated patients
with NM-BAC with FISH-positive EGFR and low levels of
MAP-K and HER2 receiving gefitinib have a significantly
longer MS.96,97
Thus, prognostic factors clearly depend on radiologic
presentation. With presentation as a nodule/mass, traditional
prognostic factors, including TNM classification, are suffi-
cient, but pathologic findings could add information, espe-
cially the proportion of BAC, absence of scar, and nonmuci-
nous pathology. However, for P-ADC and multifocal disease,
TNM staging is not useful because many T4 or M1 tumors
are so staged with lung-only involvement. Clinical and patho-
logic features associated with aerogenous spread, including
bronchorrhea, dyspnea, crepitant rales, bilaterality, consoli-
dative or diffuse disease, tumor cells in sputum, and neutro-
phil alveolitis appear to determine prognosis. Finally, several
molecular features may be associated with prognosis in both
surgically resected and advanced disease. However, these
data must be interpreted cautiously because they are from
different studies and might not be comparable for matching
other prognostic and treatment factors.
PRECLINICAL AND CLINICAL THERAPEUTIC
STUDIES AND MEDICAL MANAGEMENT
Until recently, BACs have been “lumped” with other
NSCLC patients receiving chemotherapy for advanced dis-
ease. However, there are difficulties in assessing objective
responses183,184 and natural history is long. How its respon-
siveness compares with other types is unclear. Because of
low incidence, only one prospective phase II and no phase III
studies has been published. However, the impressive effects
in advanced-disease patients with new biological agents and
its unique molecular biology have prompted prospective
studies.
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Chemotherapy in BAC
In retrospective studies, response rate (RR) and MS
with chemotherapy have not been significantly different from
non-BAC patients.18,25,26 Two prospective phase II studies
used paclitaxel as front-line treatment administered either
over 3184 or 96120 hours every 3 weeks. RR was 14% and
11%, stable disease (SD) in 50% and 40%, respectively,
resulting in MS of 8.6 and 12 months, 1-year survival of 35%,
and 3-year survival of 13 percent. However, tolerability of the
latter was poor. Only those with M-BAC and ADC-WBF
responded, with an MS of 17 to 18 months.120,184
Biological Agents
Patients with BAC-containing tumors have responded
to two EGFR TKIs, gefitinib (Iressa)185,186 and erlotinib
(Tarceva).187 Gefitinib responses occurred in chemotherapy-
naı¨ve, heavily pretreated, and performance status 2 to 4
patients. Some responses were rapid (within days), dramatic,
and durable, even with extensive, diffuse disease,188 espe-
cially in female patients of East Asian descent.118,119
A retrospective study of gefitinib-treated patients with
any degree of BAC noted a 38% RR. The odds ratio of
responding was 13.5 for BAC, 5.2 for ADC, and 1.0 for other
NSCLC. The presence of BAC was associated with sensitiv-
ity to gefitinib which, in turn, predicted a difference in MS
compared with resistance.185 These TKI results have been
confirmed in four phase II prospective studies (Table 3). RRs
ranged from 12% (P-ADC) to 19 to 29% in chemotherapy-
naı¨ve patients, somewhat lower in those having received prior
chemotherapy. TKIs appear to be most effective in these five
studies in nonsmokers or minimal smokers, females, and
Japanese patients.15,185,186,189,190
Data are also accumulating concerning the relationships
between response to TKI and mutations of EGFR and K-ras.
It seems that TKI-sensitive tumors harboring EGFR muta-
tions have an element of BAC, whereas pure BAC patients
have a lower RR.187 Mutations are generally not seen in
nonresponders.191 Never-smokers have the highest incidence
of EGFR mutations.190,192 Approximately one-fourth of
BAC-type patients should be TKI-sensitive because of mu-
tations92 and approximately 65 to 100% of all patients with
mutations have responded to a TKI.191–195 However, not all
BAC-containing tumors with major responses to a TKI have
a mutation demonstrated.191,192 FISH-positive tumors may
show longer disease control with gefitinib.96 Although certain
EGFR mutations predict TKI sensitivity, K-ras mutations
seem to predict resistance,104,196,197 especially in smokers or
in M-BAC. EGFR and K-ras mutations are rarely seen in the
same tumor.104
SYMPTOMATIC TREATMENT FOR
BRONCHORRHEA
Bronchorrhea can lead to significant morbidity, even
mortality, and may need management. Indomethacin (in-
haled), corticosteroids, macrolides, and TKIs have reduced
sputum production. Nebulized Indomethacin decreases spu-
tum within 5 days but only when sputum contained COX-2
mRNA.198,199 Corticosteroids are useful, both orally and in-
haled, either by inhibiting the COX-2 gene or by inhibition of
glycoconjugate secretion.200 Sputum reduction by TKIs can
be rapid and dramatic,188,201,202 but by an unknown mecha-
nism. Of eight reported patients having this rapid response,
three had NM-BAC, with five not specified.118,119,188,201,202
TKIs may decrease sputum production203,204 by inhibiting
mucin gene transcription, mucin synthesis, and/or goblet cell
degranulation205 induced by EGFR activation-related inflam-
matory mediators released by tumor-infiltrating inflammatory
cells.
Future Directions
Because of the above-mentioned cytotoxic and biolog-
ical responses and numerous phase I and II studies and
anecdotal reports, five phase II studies are planned or have
been initiated for patients with advanced-stage, BAC-con-
taining tumors. In one, patients will receive single-agent
cetuximab; another will test bortezomib; a third, single-agent
pemetrexed; and a fourth, erlotinib plus bevacizumab.206 A
fifth will test the hypothesis that a radiographic response to
erlotinib correlates with an EGFR mutation.207
CONCLUSIONS
BAC and the clinically and pathologically related
ADCs, Noguchi type C, ADC-WBF, P-ADC, and diffuse
disease may be increasing in industrialized countries, in both
smokers and nonsmokers, and especially in women. Reasons
TABLE 3. Recent Phase II Studies Involving Patients with Advanced Disease, Using Single-Agent TKIs as First-Line or Salvage
Therapy
Reference No. of Patients Response (%) Median Survival Treatment Study Type
Miller et al., 2004185*† 24 37.5 15 mo if sensitive, 6 mo if resistant Gefitinib Retrospective
West et al., 2004186* 69 19 PR, 6 CR, 30 SD 12 mo, 1 yr 50%; F  M Gefitinib Phase II
West et al., 2004186† 22 9 PR, 0 CR, 36 SD 10 mo, 1 yr 50%; F  M Gefitinib Phase II
Cadranel et al., 2005189* 50‡ 12, 0 CR, 18 SD Not yet reached Gefitinib Phase II
Sandler et al., 2005190* 17 29 17 mo, 71% alive at 1 yr§ Erlotinib Phase II
Sandler et al., 2005190† 67 22 17 mo, 71% alive at 1 yr§ Erlotinib Phase II
Miller et al., 200515*† 78 24 1 yr Erlotinib Phase II
*Chemotherapy-naive. †Prior chemotherapy. ‡All with P-ADC, almost all with some degree of BAC. PR, partial response; CR, complete response; SD, stable disease. §Combined
chemo-naive and prior chemo patients.
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are unclear, but environmental and genetic factors need
evaluation. This is important because AAH and BAC may be
forerunners of some ADC, which clearly is increasing.
When resectable, lobectomy with complete mediastinal
examination is usually best, including for T1 lesions. Tissue
should be examined macroscopically and, if 1.0 cm or
smaller, completely examined microscopically to make the
diagnosis of either BAC or ADC-WBF. This can change
prognosis and perhaps management. Adequate tissue samples
also may aid in molecular studies. Lesser surgery such as
segmental or wedge resection should be reserved for special
circumstances. Multiple resections for synchronous/meta-
chronous primary tumors or intrapulmonary metastases might
be appropriate, whereas curative pneumonectomy or resec-
tions for diffuse disease are not. In selected cases, lung
transplantation may be considered.
The results of recent phase II studies using paclitaxel
notwithstanding, the role of chemotherapy for BAC-type
tumors should continue to be evaluated. However, recent
knowledge of BAC biology has led to novel therapies, with
results from TKIs showing promise. Although EGFR, K-ras,
and other genetic alterations may partly explain some major
responses, or lack thereof, seen with TKIs, other biological
studies are needed to understand the up-to-50% SD and
symptom improvement rates. The inflammatory microenvi-
ronment and BAC cell characteristics, as in P-ADC, such as
motility, loss of cell-cell and cell-matrix interactions, and
resistance to apoptosis may explain aerogenous spread. Ther-
apeutically, this may help select molecules targeting these
characteristics.
A major advance will be the ability to select patients for
biological agents. Along with smoking history, gender, race,
pathologic subtype (M-BAC or NM-BAC, degree of BAC),
and specific EGFR and K-ras mutations also may predict
sensitivity/resistance and survival benefit from TKIs. Muta-
tions, alone, however, do not explain this sensitivity. Other
diagnostic studies can select patients who will benefit from
EGFR inhibition, including FISH and immunohistochemistry
evaluation of the erb-B, K-ras, MAP-K, and Akt pathways.
These may detect activated or abnormal proteins downstream
from EGFR and K-ras. Thus, a combination of clinical and
laboratory procedures may be needed to better predict drug
sensitivity and outcome.
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